A greater burden of atrial fibrillation is associated with worse endothelial dysfunction in hypertension by Khan, Ahsan A et al.
  Page 1 of 26 
 
A greater burden of atrial fibrillation is associated with worse endothelial 1 
dysfunction in hypertension 2 
Short title: Endothelial function in AF and hypertension 3 
Ahsan A Khan, MRCP1 4 
Rehan T Junejo, PhD2,3 5 
Reem Alsharari, MSc4 6 
Graham N Thomas, PhD1 * 7 
James P Fisher, PhD5 * 8 
Gregory Y.H. Lip, MD3,6 * 9 
1. Institute of Applied Health Research, University of Birmingham, United Kingdom 10 
2. School of Sport, Exercise and Rehabilitation Sciences, College of Life and 11 
Environmental Sciences, University of Birmingham, United Kingdom 12 
3. Liverpool Centre for Cardiovascular Science, Institute of Ageing and Chronic Disease, 13 
University of Liverpool, United Kingdom 14 
4. Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom 15 
5. Department of Physiology, Faculty of Medical and Health Sciences, University of 16 
Auckland, New Zealand 17 
6. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of 18 
Health, Aalborg University, Denmark 19 
*Joint senior authors 20 
Correspondence to: 21 
Professor Gregory Lip  gregory.lip@liverpool.ac.uk  22 
Full mailing address  University of Liverpool, William Henry Duncan Building, 6 West  23 
Derby Street, Liverpool, L7 8TX 24 
Telephone number  0151 794 9020 25 
Word count: 4224 (not including abstract, figures, tables and references) 26 
27 




Atrial fibrillation (AF) and hypertension often co-exist and both are associated with 30 
endothelial dysfunction. We hypothesised that AF would further worsen endothelium-31 
dependent flow-mediated dilatation (FMD) in hypertension patients compared to those 32 
without AF. In a cross-sectional comparison, we measured brachial artery diameter at rest 33 
and during reactive hyperaemia following 5 minutes of arterial occlusion in two patient 34 
groups: AF (and hypertension) (n = 61) and hypertension control groups (n = 33). The AF 35 
(and hypertension) subgroups: permanent AF (n = 30) and paroxysmal AF (n = 31) were also 36 
assessed. The permanent AF patients received heart rate and blood pressure (BP) control 37 
optimisation and were then followed up after eight weeks for repeat FMD testing. There 38 
was no significant difference in FMD between AF (and hypertension) group and 39 
hypertension control group (4.6%, 95% CI [2.6 – 5.9%] vs 2.6%, 95% CI [1.9 – 5.3%]; p=0.25). 40 
There was a significant difference in FMD between permanent AF and paroxysmal AF groups 41 
(3.1%, 95% CI [2.3 – 4.8%] vs 5.9%, 95% CI [4.0 – 8.1%]; p=0.02). Endothelium-dependent 42 
FMD response showed a non-significant improvement trend following eight weeks of heart 43 
rate and BP optimisation (3.1%, 95% CI [2.3 – 4.8%] (baseline) vs 5.2%, 95% CI [3.9 – 6.5%] 44 
(follow up), p=0.09). Presence of AF generally does not incrementally worsen endothelial 45 
dysfunction in hypertension patients, although the duration and frequency of AF 46 
(paroxysmal AF to permanent AF) does lead to worsening endothelial function. Eight weeks 47 
of BP optimisation did not significantly improve endothelial dysfunction as measured by 48 
FMD. 49 
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Introduction 51 
Atrial fibrillation (AF) is associated with increased morbidity including stroke, heart failure, 52 
thromboembolic complications and high mortality.1 Hypertension accounts for more cases 53 
of AF than other risk factors, increasing the risk of AF two-fold.2 In the Framingham study, 54 
for example, hypertension heralded an excess risk of AF by 50% in males and 40% in 55 
females.3 Among individuals with a confirmed diagnosis of AF, hypertension is present in 56 
about 60% to 80% of these patients.4 These 2 conditions often co-exist in the same patient, 57 
and their prevalence is increasing globally. It is widely perceived that the combination of 58 
these conditions confers a worse prognosis than either alone.5 59 
Beat to beat variation in blood flow dynamics during AF has been related to presence of 60 
endothelial dysfunction.6 It is well established that the endothelium plays a fundamental 61 
role in the regulation of vascular tone by releasing a variety of vasodilatory substances, 62 
particularly nitric oxide (NO). NO modulates vascular smooth muscle tone by exerting its 63 
effects at a cellular level. A key consequence of normal endothelial function in vivo is the 64 
ability to release NO in response to physiological stimuli, such as increased flow, reflecting 65 
endothelial flow-mediated dilatation (FMD).7  66 
Impaired FMD is associated with cardiovascular risk factors and provides important 67 
prognostic information. FMD measurement using high-resolution ultrasound has become a 68 
reliable and reproducible technique for assessment of endothelial dysfunction.8 When blood 69 
flow through a vessel increases, the resultant increase in shear stress on the vascular 70 
endothelium causes endothelium-dependent vasodilation. The magnitude of this 71 
vasodilatory response can be used as an index of endothelial function.  72 
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Several studies have previously shown impaired FMD as a marker of endothelial dysfunction 73 
in patients with various atherosclerotic risk factors, including advanced age, hypertension, 74 
hypercholesterolaemia, diabetes mellitus, tobacco use and postmenopausal status.9-12 FMD 75 
is also found to be impaired in patients with AF.13-16 Since AF and hypertension, commonly 76 
co-exist, we hypothesised that endothelium-dependent FMD will be reduced in patients 77 
with AF (and hypertension) compared to hypertensive controls and this may partly explain 78 
the poor prognosis in such patients.  79 
We therefore aimed to assess whether presence of AF leads to worsening of endothelial 80 
dysfunction in hypertensive patients through assessment by FMD, to assess whether there 81 
are any differences in FMD between permanent AF and paroxysmal AF, and lastly whether 82 
improvement in blood pressure (BP) control can lead to improvement in FMD. 83 
Methods 84 
Participants were provided with detailed information sheets, and written informed consent 85 
was obtained from all participants, in accordance with the Declaration of Helsinki (2013).  86 
Eligible participants underwent screening against inclusion and exclusion criteria before 87 
being invited to take part in the study (see supplementary material). The study was 88 
approved by the Health Research Authority (HRA) and National Research and Ethics Service 89 
(NREC) Committee London – Camden & Kings Cross (18/LO/1064). Anonymized data and 90 
materials have been made publicly available at the Harvard Dataverse and can be accessed 91 
at https://doi.org/10.7910/DVN/QKG7DL. 92 
A total of 94 participants were recruited from the atrial fibrillation and hypertension 93 
services at Sandwell and West Birmingham Hospitals NHS Trust between October 2018 – 94 
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March 2019. We recruited 2 groups of patients: AF (and hypertension) (n = 61) and 95 
hypertension control (n = 33). Patients with AF were stable on rate control and 96 
antithrombotic medication. The AF (and hypertension) group was further subdivided into 97 
permanent AF (n = 30) and paroxysmal AF (n = 31). Permanent AF was defined as an episode 98 
of AF in which efforts to restore normal sinus rhythm had either failed or been abandoned. 99 
Paroxysmal AF was defined as an episode of AF that terminates spontaneously or with 100 
intervention in less than seven days. The hypertension control group included patients with 101 
hypertension (defined as previous diagnosis of hypertension or clinic BP of ≥140/90 mmHg) 102 
but not AF. These patients had additional cardiovascular risk factors similar to the other two 103 
AF groups and acted as the control group.  104 
Initially, a cross-sectional age and clinical characteristics-matched comparison of the two 105 
main groups, AF (and hypertension) versus hypertension control was carried out. This was 106 
followed by the two subgroups of AF (and hypertension) group. Lastly, the patient group 107 
with permanent AF (and hypertension) (n = 30) were studied longitudinally with a single 108 
follow-up interval of 8 weeks duration following optimisation of their heart rate (HR) and BP 109 
medication. The medication optimisation was carried out by a single clinician with 110 
experience in managing these conditions and involved either increasing the dosage of 111 
existing cardiovascular medication or addition of a new medication (for which the 112 
prescription was provided) according to participants’ needs, allergy status, known 113 
contraindications and clinical indication. These patients underwent the same measurements 114 
as at their first visit.  115 
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Experimental protocol 117 
Participants were expected to fast from food, water, caffeine and withhold their 118 
cardiovascular medications, except anticoagulation, for at least 12 hours prior to their 119 
appointment. They were advised to refrain from smoking for at least 4 hours, physical 120 
exercise for 12 hours and drinking alcohol for at least 24 hours prior to their appointment. 121 
At the experimental appointment, a detailed medical history was taken from the 122 
participants including medications history and a physical examination carried out. This 123 
included anthropometric measurements such as height and weight to determine BMI 124 
(weight/height2; kg/m2). An ECG was performed on all participants to determine rhythm.  125 
Baseline blood samples to test for full blood count, renal, liver and thyroid function, fasting 126 
glucose, lipid, and clotting profile, were taken from participants from their left antecubital 127 
fossa if they have not had these tests taken within 6 months of their study appointment. A 128 
full transthoracic echocardiogram study was performed if a participant did not have a recent 129 
echocardiogram. Subsequent measurements were performed in a temperature-controlled 130 
room under uniform conditions with participants resting quietly in the supine position on a 131 
medical examination couch.  132 
Measurements 133 
Three serial BP readings were taken non-invasively from the left brachial artery using an 134 
automated sphygmomanometer over 5 minutes to determine an average. Vascular function 135 
was assessed by measuring brachial artery blood flow velocity and diameter. The 136 
measurements were obtained from the right arm positioned at heart level by Doppler 137 
ultrasound (CX50 CompactXtreme; Philips, Amsterdam, Netherlands) by a single 138 
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experimenter, using a 10-MHz multi-frequency linear-array transducer. B-mode imaging was 139 
used to measure arterial diameter, and peak blood velocity was simultaneously measured 140 
using the pulse-wave mode. Measurements were made in accordance with recent technical 141 
recommendations.17 The ultrasound machine was connected via a HDMI AV.io (Epiphan 142 
Video Systems Inc, California, USA) video grabber to a laptop with a dedicated FMD 143 
software, QUIPU Cardiovascular Suite (Quipu srl, Pisa, Italy) with edge-detection capability 144 
and real-time processing and recording of B-mode ultrasound image sequence, removing 145 
the need for ECG gating.18 This software utilises image based automated edge detection and 146 
wall tracking algorithms working independently of investigator influence. This system has 147 
been used and validated in other studies involving human participants.18, 19 148 
Participants lay supine on the couch with their right arm extended out and had a narrow 149 
inflatable cuff (5-cm width; Hokanson, Bellevue, WA) placed 5 – 7 cm distal to the medial 150 
epicondyle. The arm was positioned in a comfortable position. The brachial artery was 151 
imaged 10-15 cm proximal to the medial epicondyle at 60o insonation angle in the 152 
longitudinal plane. Duplex imaging was used to obtain a B-mode image of vessel diameter 153 
and pulse-wave mode for peak blood velocity. Ultrasound measurements were made in 154 
accordance with technical recommendations.17 Following 1 minute of baseline diameter 155 
recording, the arterial occlusion cuff was inflated to 50 mmHg above systolic BP for 5 156 
minutes. Following this, the cuff was rapidly deflated and arterial image recording continued 157 
for further 2 minutes. Recordings were screen captured and stored as video files and off-line 158 
analysis carried out with automated edge detection and wall tracking software 159 
(Cardiovascular Suite version 3.4.1; FMD Studio, Pisa, Italy). 160 
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Data analysis 162 
Patients were matched for age and clinical characteristics to reduce chances of 163 
confounders. Body mass index (BMI) was expressed as the ratio of the participants’ weight 164 
and their height squared. Digitally recorded data were extracted in an anonymized manner. 165 
Mean arterial pressure (MAP) was the mean blood pressure over each cardiac cycle. 166 
Brachial artery FMD was taken as the maximal change in brachial artery diameter following 167 
cuff deflation. The time to peak diameter was obtained between the cuff deflation and the 168 
maximal artery dilation, and the time to peak blood flow (reactive hyperaemia) was 169 
obtained between cuff deflation and maximal flow velocity. Shear rate (positive shear rate 170 
area to peak) was calculated as an integral between the cuff deflation and the maximal 171 
artery dilation. FMD was expressed as absolute (mm) and relative change (%) in diameter. 172 
Based on recent guidelines, covariate-corrected FMD was presented, adjusting for 173 
differences in baseline diameter between the two groups using analysis of covariance 174 
(ANCOVA).20 175 
Statistical analysis 176 
Descriptive statistics are presented as mean ± standard deviation (SD) or median with 177 
interquartile range, as appropriate for continuous variables. Categorical variables are 178 
expressed as numbers and percentages. Statistical analysis was performed using SPSS 179 
software (version 26.0; SPSS Inc., Chicago, Illinois). Continuous variables were tested for 180 
normality using the Shapiro-Wilk test. If passed, data was analysed using independent 181 
Student’s t-test between the two groups. Data found to be not normally distributed were 182 
analysed with Mann-Whitney U test. For longitudinal comparison, continuous variables 183 
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were tested for normality using the Shapiro-Wilk test. If passed, data was analysed using 184 
Student’s paired t-test. Data found to be not normally distributed were analysed with 185 
Wilcoxon Signed Rank test. A p value of < 0.05 was considered statistically significant. 186 
Associations between FMD and co-variates were assessed before and after adjustment for 187 
potential confounders (age, sex, BMI) using linear regression analysis. 188 
To test specific hypothesis 1 (“Patients with AF and hypertension will have worse 189 
parameters of vascular function compared to hypertension control group”), we recruited 94 190 
patients in total, split between 2 groups (a) AF and hypertension (b) hypertension control. 191 
This part of the study was powered based on independent t-test, comparing the flow-192 
mediated dilatation values across the two groups. Skalidis et al reported a mean FMD of 8.1 193 
(standard deviation (SD) = 3.6) in a pre-treatment (i.e. cardioversion) AF group.6 Assuming 194 
our SD is similar, the minimum sample size was computed as 18 patients per group at 90% 195 
power, 5% alpha and effect size of 1.14. 196 
To test specific hypothesis 2 (“Patients with permanent AF and hypertension will have 197 
worse parameters of vascular function compared to patients with paroxysmal AF and 198 
hypertension”), we recruited 61 patients in total, split between the 2 groups. This part of 199 
the study was powered based on an independent t-test, assessing the difference in FMD 200 
between permanent AF and paroxysmal AF. Mazaris et al reported a mean FMD of 4.09 (SD 201 
= 1.67) in permanent AF group compared to mean FMD of 6.83 (SD = 1.38) in paroxysmal AF 202 
group.16 Assuming our SD is similar, the minimum sample size was computed as 8 patients 203 
per group at 90% power, 5% alpha and effect size of 1.79. 204 
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To test specific hypothesis 3 (“Eight weeks of intensive anti-hypertensive and 205 
anticoagulation therapy will improve vascular function in patients with permanent AF and 206 
hypertension”) we recruited 30 patients and tested them before and after intensification of 207 
their antihypertensive and anticoagulation treatment. This part of the study was powered 208 
based on a paired t-test, assessing the change in flow mediated dilation from pre- to post- 209 
treatment. It was assumed that the mean pre- intervention flow mediated dilation would be 210 
8.1 (SD=3.6), as per Skalidis et al, and that the effect size would be 1.06.6 If this is the case, 211 
then the minimum number of patients required is 12 at 90% power and 5% alpha. 212 
Results 213 
Matched AF (and hypertension) group vs matched hypertension control group 214 
Participants from AF (and hypertension) group and hypertension control group were 215 
matched for age and clinical characteristics (see table 1). Participants’ medication history is 216 
displayed in figure 1. There were no significant differences in age, sex, height, weight and 217 
BMI. Past medical history of all participants between the groups was similar except that 218 
participants in hypertension control group had significantly more patients with a 219 
background of chronic kidney disease (CKD) (p = 0.01). The CHA2DS2-VASc score and HAS-220 
BLED score were similar between the two groups. The mean heart rate was significantly 221 
lower in the hypertension control group (p = 0.02). There were no significant differences in 222 
mean blood pressure (systolic and diastolic) between the two groups, baseline glycaemia 223 
control (HBA1c), kidney function (creatinine clearance) and left ventricular ejection fraction 224 
(EF (%)).  225 
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Baseline diameter of brachial artery was significantly smaller in the AF (and hypertension) 226 
group compared to hypertension control group (4.6 mm, 95% confidence interval (CI) [4.4 – 227 
4.9 mm] vs 5.2 mm, 95% CI [4.8 – 5.6 mm]; p = 0.02) (see table 2). Following 5 minutes of 228 
forearm ischaemia, there was no significant difference in absolute FMD between AF (and 229 
hypertension) group and hypertension control group (0.2 mm, 95% CI [0.1 – 0.3 mm] vs 0.2 230 
mm, 95% CI [0.1 – 0.3 mm]; p = 0.61) or FMD percentage (4.6%, 95% CI [2.6 – 5.9%] vs 2.6%, 231 
95% CI [1.9 – 5.3%]; p = 0.25) respectively. The FMD (%) means were adjusted for baseline 232 
diameter and showed no significant difference between the two groups (4.9%, 95% CI [3.8 – 233 
6.0%] (AF (and hypertension) group) vs 4.3%, 95% CI [2.8 – 5.9%] (hypertension control 234 
group), p = 0.56). 235 
The peak diameter was significantly different between the two groups (4.9 mm, 95% CI [4.6 236 
– 5.2 mm] (AF (and hypertension) group) vs 5.4 mm, 95% CI [5.0 – 5.8 mm] (hypertension 237 
control group); p = 0.03). There were no significant differences in time to peak diameter and 238 
shear rate between the two groups (p = 0.07 and p = 0.41 respectively). No variables were 239 
identified on univariate and stepwise multivariate analysis as independent predictors of 240 
reduced FMD.  241 
Permanent AF (and hypertension) vs PAF (and hypertension) groups 242 
Participants in the two AF subgroups (permanent AF vs paroxysmal AF) were well matched 243 
for age, sex, clinical characteristics including height, weight, BMI, mean blood pressure, 244 
HBA1c, creatinine clearance and left ventricular EF (%) (see table 3). Participants’ 245 
medication history is displayed in figure 1. There was a significantly higher incidence of 246 
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ischaemic heart disease in paroxysmal AF group (p<0.001) and mean heart rate was found 247 
to be significantly slower in participants in paroxysmal AF group (p = 0.003). 248 
On FMD measurement, there were no significant difference in baseline diameter between 249 
the two groups (permanent AF (4.5 mm, 95% CI [4.2 – 5.0 mm]) vs paroxysmal AF (4.8 mm, 250 
95% CI [4.6 – 5.1 mm]) p = 0.67) (see table 4). Following 5 minutes of forearm ischaemia, 251 
there was a significant difference in absolute FMD change between permanent AF and 252 
paroxysmal AF (0.1 mm, 95% CI [0.1 – 0.2 mm] vs 0.3 mm, 95% CI [0.2 – 0.4 mm]; p = 0.01 253 
respectively). There was also a significant difference in FMD percentage between the two 254 
groups (3.1%, 95% CI [2.3 – 4.8%] (permanent AF) vs 5.9%, 95% CI [4.0 – 8.1%] (paroxysmal 255 
AF); p = 0.02). This difference persisted with correction for baseline diameter (3.9%, 95% CI 256 
[2.8 – 5.0%] (permanent AF) vs 5.9%, 95% CI [4.8 – 7.0%] (paroxysmal AF); p = 0.01).  257 
There was no significant difference in peak diameter (p = 0.49), time to peak diameter (p = 258 
0.23) and shear rate (p = 0.40) between the two groups. Presence of permanent AF 259 
(Spearman’s rho 0.295; p = 0.02) and ischaemic heart disease (Spearman’s rho 0.280; p = 260 
0.03) were identified as independent predictors of reduced FMD on univariate analysis (p = 261 
0.03) but only permanent AF was identified as an independent predictor of reduced FMD on 262 
stepwise multivariate analysis (R2 0.090; F 5.855; p = 0.02). 263 
Permanent AF (and hypertension) group – longitudinal comparison 264 
Following optimisation of HR and BP medication, patients with permanent AF (and 265 
hypertension) were followed up after eight weeks and FMD repeated (see table 5). There 266 
was significant improvement in mean heart rate (77 beats per minute (bpm) ± 18 (baseline) 267 
vs 72 bpm ± 17 (follow up), p = 0.01), systolic BP (140 mmHg [128 – 148] (baseline) vs 131 268 
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mmHg [122 – 146] (follow up), p = 0.03), diastolic BP (81 mmHg ± 13 (baseline) vs 77 mmHg 269 
± 12 (follow up), p = 0.02) and mean arterial pressure (MAP) (100 mmHg ± 9 (baseline) vs 97 270 
mmHg ± 13 (follow up), p = 0.01).    271 
Both groups had a similar baseline brachial artery diameter (p = 0.34). Endothelium-272 
dependent FMD response was better following eight weeks of HR and BP optimisation but 273 
this 68% relative improvement did not reach statistical significance (3.1%, 95% CI [2.3 – 274 
4.8%] (baseline) vs 5.2%, 95% CI [3.9 – 6.5%] (follow up), p = 0.09). The FMD (%) means 275 
were adjusted for baseline diameter and showed no significant difference between the two 276 
groups (4.0%, 95% CI [3.0 – 4.9%] (baseline) vs 5.1%, 95% CI [4.2 – 6.1%] (follow up), p = 277 
0.09). The difference was also not significant in absolute change in diameter (0.14 mm, 95% 278 
CI [0.11 – 0.25 mm] (baseline) vs 0.20 mm, 95% CI [0.17 – 0.28 mm] (follow up), p = 0.15). 279 
The time to peak diameter, peak diameter and shear rate stimulus were similar between the 280 
two groups (table 5). No variables were identified on univariate or stepwise multivariate 281 
analysis as independent predictors of reduced FMD. 282 
Discussion 283 
This is the first study investigating whether the presence of AF worsens the endothelial 284 
dysfunction seen in patients with hypertension. The results are consistent with other studies 285 
looking at FMD in hypertension and AF individually and confirms that endothelial 286 
dysfunction is present.9, 13-16, 21 Our findings extend previous work by demonstrating that the 287 
presence of AF generally does not incrementally worsen endothelial dysfunction, nor was AF 288 
an independent predictor of endothelial dysfunction on multivariate analysis. However, 289 
permanent AF compared to paroxysmal AF does have significantly worse FMD parameters 290 
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with permanent AF being an independent predictor on multivariate analysis. Lastly, we did 291 
not find any significant improvement in FMD following 8 weeks of HR and BP optimisation in 292 
permanent AF and hypertension patients.  293 
There are potentially several reasons that may explain the lack of differences seen between 294 
AF (and hypertension) and hypertension control group in our study. These can be broadly 295 
categorised into oxidative stress, inflammation and the role of endothelial nitric oxide 296 
synthase (eNOS). Increase in systemic oxidative stress is thought to play a part in endothelial 297 
dysfunction seen in patients with hypertension, whereas a reduction has been shown to 298 
reverse endothelial dysfunction.22 Risk factors for AF are similar to those of atherosclerosis 299 
and hypertension, diseases known to be perpetuated by oxidative stress. This can explain 300 
why the addition of AF does not significantly worsen endothelial dysfunction seen in 301 
patients with hypertension. 302 
Inflammation has also been implicated in the pathophysiology of hypertension as well as 303 
initiation and perpetuation of AF and AF-related adverse effects.23, 24 Endothelial 304 
dysfunction seen in hypertension relates to local vascular inflammation and systemic 305 
inflammation.25 Also, inflammation contributes to the pathophysiology of AF, both directly 306 
and through AF-promoting cardiovascular conditions that have an inflammatory aetiology.26 307 
FMD has been shown to be inversely associated with serum C-reactive protein (CRP) levels 308 
in chronic AF patients, implying disruption by inflammation.27 Since inflammation plays an 309 
important role in causing endothelial dysfunction in both conditions, it is perhaps 310 
unsurprising that we did not see a significant difference in the FMD response between the 311 
groups, suggesting that endothelial perturbation seen in AF may reflect underlying 312 
comorbidities rather than AF per se. Interestingly, endothelial dysfunction itself enhances 313 
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oxidative stress and leads to increase in recruitment of proinflammatory agents promoting a 314 
vicious cycle.28 The complex interplay involving oxidative stress and inflammation seen in 315 
both conditions is summarised in figure 2. 316 
eNOS, a key regulator of vascular tone is found to be reduced or dysfunctional in both 317 
hypertension and AF.29, 30 eNOS produces NO to mediate relaxation of blood vessels and 318 
preservation of vascular function. When eNOS is deprived of its critical cofactor 319 
tetrahydrobiopterin or its substrate L-arginine, it results in synthesis of large volumes of 320 
reactive oxygen species such as peroxynitrite (superoxide) instead of NO, leading to nitric 321 
oxide synthase (NOS) uncoupling. Superoxide production by uncoupled eNOS further 322 
sustains oxidative stress in the vasculature, resulting in endothelial dysfunction, impaired 323 
endothelium-dependent vasorelaxation and elevated BP.29 This inadvertently leads to tissue 324 
damage that promotes pathological remodelling of the myocardium contributing to 325 
initiation and propagation of AF.31 Since the aetiology and pathophysiology of endothelial 326 
dysfunction are similar in both hypertension and AF, this supports our finding that AF and 327 
hypertension had similar effect on the FMD with no significant difference seen between the 328 
two groups. Our study also suggests that AF, as opposed to hypertension, is perhaps the 329 
dominant condition responsible for endothelial dysfunction in these patients as permanent 330 
AF group showed a worse FMD compared to paroxysmal AF group and 8 weeks of intensive 331 
hypertensive therapy revealed a non-significant improvement trend in FMD. 332 
Interestingly, we were able to see a significant difference in FMD between permanent AF 333 
and paroxysmal AF groups with more impaired FMD noted in permanent AF group. This 334 
suggests that frequency and duration of AF episode or type of AF may be important in 335 
progression of endothelial dysfunction. Our findings are similar to other studies showing 336 
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that patients with permanent AF have worse FMD compared to patients with paroxysmal 337 
AF.15, 16, 32 However, unlike previous studies, our study included patients with AF and 338 
hypertension, which has not been looked at before. 339 
Although, our study did show that improvement in HR and BP can lead to improvement in 340 
FMD in hypertensive patients despite the presence of AF, however this 68% improvement 341 
did not reach statistical significance (p = 0.09). These results are similar to the study 342 
performed by Modena and colleagues who looked at hypertensive patients (without AF) and 343 
showed that 6 month of BP optimisation led to improvement in FMD and was associated 344 
with a more favourable prognosis.33 Thus, longer-term improvement in FMD may have a 345 
prognostic implication.34 Furthermore, it supports previous work showing modulation of 346 
endothelial function is possible and that endothelial dysfunction is a reversible condition.25  347 
Our study has several important clinical implications. We have been able to show that 348 
endothelial dysfunction is present in patients with AF and hypertension. This may explain 349 
the increased risk of stroke and heart attack in these patients as endothelial function may 350 
be involved in the pathophysiology of these conditions, in addition to the prothrombotic 351 
state seen in AF. We have been able to show that increased frequency and duration of AF 352 
leads to worsening of endothelial function and thus these patients may benefit from closer 353 
monitoring and perhaps consideration for AF ablation. We have also shown that 354 
improvement in HR and BP leads to improvement in FMD, although it was not significant in 355 
our study. Nevertheless, it does suggest that endothelial function may be a reversible 356 
condition if risk factors such as blood pressure are controlled and optimised. 357 
  358 
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Strengths and limitations 359 
We did not use nitrate to assess for endothelium-independent vasodilation as this has been 360 
studied previously in both AF and hypertension.9, 13, 15, 21 Furthermore, use of intra-arterial 361 
acetylcholine would have been advantageous to investigate brachial artery endothelial 362 
function but FMD is a well established surrogate.17 Given the widespread prevalence of AF 363 
in hypertensive patients, the inclusion of separate hypertension groups with and without 364 
AF, is a strength of our study. There have been limited studies looking at vascular function in 365 
patients with AF arrhythmia and therefore this makes our study unique. Participants in our 366 
group were well-matched for age, sex composition, comorbidities, CHA2DS2-VASc score, 367 
HAS-BLED score, BMI, BP, glycaemic control and LV systolic function. Nonetheless, the 368 
hypertension control group did have a significantly higher number of patients with CKD 369 
which may have been a source of bias. We accommodated for this and other potential 370 
confounders by utilisation of linear regression analysis. The longitudinal comparison of 371 
permanent AF (and hypertension) group in assessing FMD response to intervention has not 372 
been looked at before. The utilisation of edge detection software, assessment of shear rate 373 
and correcting for differences in group baseline diameters shows robustness of our 374 
methodological approach. 375 
In contrast, our study has some limitations. Endothelial function was examined using the 376 
well-established brachial artery flow mediated dilatation technique in accordance with 377 
recent technical recommendations, however we acknowledge that this may not provide an 378 
optimal assessment of endothelial dysfunction.17 Second, it would have been useful to 379 
compare our findings with a healthy control group and/or a group with AF but no 380 
hypertension as the relation between hypertension and AF is bi-univocal. Third, the use of 381 
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anti-hypertensives and other concomitant medications may have influenced endothelial 382 
function long term which cannot be excluded. Additionally, whilst we were able to show 383 
reduction in HR and BP in our longitudinal study, the short duration of 8 weeks may not be 384 
enough to reveal significant improvement in endothelial function. Fourth, we did not 385 
measure other potential causes for endothelial dysfunction such as changes in free fatty 386 
acids, inflammatory cytokines, inflammatory markers such as c-reactive protein (CRP), nitric 387 
oxide synthase expression and endothelin. However, this real world cohort has ecological 388 
validity and makes our observations more representative of the clinic. Future studies should 389 
look at whether and how endothelial function progresses in patients with AF over time and 390 
compare it to patients with hypertension to assess if there are any differences. 391 
Conclusions 392 
The presence of AF generally does not incrementally worsen endothelial dysfunction in 393 
hypertension, nor was AF an independent predictor of endothelial dysfunction on 394 
multivariate analysis. However, duration and frequency of AF leads to worsening endothelial 395 
function as demonstrated in our study. Eight weeks of BP optimisation did not give a 396 
significant improvement in endothelial dysfunction as measured by FMD. 397 
  398 
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Summary Table 399 
What is known about topic? 
• Atrial fibrillation and hypertension commonly co-exist and the combination of 
these two conditions confers a worse prognosis than either alone. 
• Endothelial dysfunction is present in both atrial fibrillation and hypertension. 
• Flow-mediated dilatation is a reliable tool to assess endothelial function.  
What this study adds? 
• Presence of AF generally does not incrementally worsen endothelial dysfunction in 
hypertension patients 
• The duration and frequency of AF (paroxysmal AF to permanent AF) does lead to 
worsening endothelial function.  
• There is potential for endothelial dysfunction to improve following optimisation of 
BP suggesting modulation of endothelial function is possible in patients with 
permanent AF and hypertension. 
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Legends 508 
Figure 1 509 
Medication use by class of drugs 510 
ACE inhibitor = Angiotensin converting enzyme; ARB = Angiotensin receptor blocker 511 
Figure 2  512 
Complex interplay between hypertension, AF, oxidative stress, inflammation and 513 
endothelial dysfunction 514 
Table 1 515 
Descriptive data are presented as numbers (with percentages). Normally distributed data 516 
are expressed as mean ± standard deviation. Non-normally distributed data are displayed as 517 
median with interquartile ranges. Statistical differences were tested for matched groups 518 
using an independent t-test for normally distributed data and Mann-Whitney U test for non-519 
normally distributed data. Categorical data was compared using Chi-square test. Where Chi-520 
square test was not valid, Fisher’s Exact Test was used. Significance p ≤ 0.05. - = unable to 521 
calculate p value as sample size too small/statistical test not valid 522 
AF = atrial fibrillation; TIA = Transient Ischaemic Attack; COPD = Chronic Obstructive 523 
Pulmonary Disease; BMI = Body Mass Index; bpm = beats per minute; BP = blood pressure; 524 
HbA1c = Haemoglobin A1C; CrCl = Creatine Clearance (Cockroft-Gault method); TSH = 525 
Thyroid Stimulating Hormone; INR = International Normalised Ratio 526 
 527 
Table 2 528 
 529 
Normally distributed data are expressed as mean [95% confidence intervals (CI)]. Identified 530 
by superscript a. Non-normally distributed data are displayed as median [95% CI]. Identified 531 
by superscript b. Statistical differences were tested for matched groups using independent 532 
t-test (for parametric data) or Mann-Whitney U test (for non-parametric data). Significance 533 
p ≤ 0.05. 534 
AF = atrial fibrillation; FMD = flow-mediated dilatation; FMDc = FMD % mean [95% CI] 535 
adjusted for baseline diameter 536 
Table 3 537 
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Descriptive data are presented as numbers (with percentages). Normally distributed data 538 
are expressed as mean ± standard deviation. Non-normally distributed data are displayed as 539 
median with interquartile ranges. Statistical differences were tested using an independent t-540 
test for normally distributed data and Mann-Whitney U test for non-normally distributed 541 
data. Categorical data was compared using Chi-square test. Where Chi-square test was not 542 
valid, Fisher’s Exact Test was used. Significance p ≤ 0.05. - = unable to calculate p value as 543 
sample size too small/statistical test not valid 544 
AF = atrial fibrillation; TIA = Transient Ischaemic Attack; COPD = Chronic Obstructive 545 
Pulmonary Disease; BMI = Body Mass Index; bpm = beats per minute; BP = blood pressure; 546 
HbA1c = Haemoglobin A1C; CrCl = Creatine Clearance (Cockroft-Gault method); TSH = 547 
Thyroid Stimulating Hormone; INR = International Normalised Ratio 548 
 549 
Table 4 550 
Normally distributed data are expressed as mean [95% confidence intervals (CI)]. Identified 551 
by superscript a. Non-normally distributed data are displayed as median [95% CI]. Identified 552 
by superscript b. Statistical differences were tested using independent t-test (for parametric 553 
data) or Mann-Whitney U test (for non-parametric data). Significance p ≤ 0.05. 554 
AF = atrial fibrillation; FMD = flow-mediated dilatation 555 
 556 
Table 5 557 
Normally distributed data are expressed as mean ± standard deviation for descriptive data 558 
and mean [95% confidence interval (CI)] otherwise. Identified by superscript a. Non-559 
normally distributed data are displayed as median with interquartile ranges for descriptive 560 
data and median [95% CI] otherwise. Identified by superscript b. Normality test was 561 
performed using Shapiro-Wilk test. Statistical differences were tested using paired t-test (if 562 
passed) or Wilcoxon signed rank test (if failed). Significance p ≤ 0.05. AF = atrial fibrillation; 563 
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Table 1 – Demographics and clinical characteristics of matched AF (and hypertension) group and 
hypertension control group  
 
 AF + hypertension 
group 
(n = 40) 
Hypertension control 
group 

















Caucasians, n (%) 
Blacks, n (%) 
Asians, n (%) 














Heart failure, n (%) 2 (5%) 0 (0%) 0.55 
IHD, n (%) 5 (12.5%) 5 (25%) 0.28
Diabetes Mellitus, n (%) 10 (25%) 8 (40%) 0.23 
Previous stroke/TIA, n (%) 5 (12.5%) 5 (25%) 0.28 
Asthma/COPD, n (%) 5 (12.5%) 2 (10%) 0.57
Chronic liver disease, n (%) 0 (0%) 0 (0%) - 
Chronic kidney disease, n (%) 1 (2.5%) 5 (25%) 0.01 
Anaemia, n (%) 0 (0%) 2 (10%) 0.11 
Thyroid disorder, n (%) 3 (7.5%) 4 (20%) 0.21
Hypercholesterolaemia, n (%) 19 (47.5%) 11 (55%) 0.58 
Arthritis, n (%) 24 (60%) 8 (40%) 0.14 
CHA2DS2-VASc score 2 [2 – 4] 3 [1 – 4] 0.74
HAS-BLED score 1 [1 – 1] 2 [1 – 2] 0.06 
Smoking status 
Never smoked, n (%) 
Ex-smoker, n (%) 












None, n (%) 






Height (cm) 170.1 ± 8.9 169.4 ± 11.1 0.80
Weight (kg) 95.5 ± 18.4 92.3 ± 14.7 0.50 
BMI (kg/m2) 32.9 ± 5.2 32.1 ± 4.2 0.58 
Heart rate (bpm) 70 [60 – 82] 63 [58 – 67] 0.02
Systolic BP (mm/Hg) 142 [133 – 152] 148 [135 – 175] 0.12 
Diastolic BP (mm/Hg) 83 ± 14 85 ± 13 0.53 
Mean Arterial Pressure (MAP) (mm/Hg) 103 ± 15 109 ± 16 0.23 
HbA1c (mmol/mol) 41 [39 – 48] 45 [38 – 56] 0.32
CrCl (mL/min) 98.8 ± 29.6 85 ± 28.1 0.09 
Ejection fraction (%) 58 ± 11 62 ± 7 0.14
 
Table 2 – Differences in flow mediated dilatation (FMD) between matched AF (and hypertension) and hypertension control groups – cross sectional 
comparison 
 AF + hypertension group 
(n = 40) 
Hypertension control group 
(n = 20) 
Matched groups 
p 
Baseline diameter (mm) 4.6 [4.4 – 4.9]a 5.2 [4.8 – 5.6]a 0.02 
Peak diameter (mm) 4.9 [4.6 – 5.2]a 5.4 [5.0 – 5.8]a 0.03 
Absolute FMD change (mm) 0.2 [0.1 – 0.3]b 0.2 [0.1 – 0.3]b 0.61
FMD (%) 4.6 [2.6 – 5.9]b 2.6 [1.9 – 5.3]b 0.25 
FMDc (%) 4.9 [3.8 – 6.0]a 4.4 [2.7 – 6.0]a 0.60 
Time to peak diameter (sec) 58 [40 – 90]b 36 [21 – 65]b 0.07 
Shear rate (Positive shear rate area to peak) [sec.-1] 4421 [2800 – 6077]b 3300 [1296 – 6887]b 0.41
 
Table 3 – Demographics and clinical characteristics of permanent AF (and hypertension) group and 
paroxysmal AF (and hypertension) group  
 
 Permanent AF + 
hypertension group 
(n = 30) 
Paroxysmal AF + 
hypertension group 
(n = 31) 
p 
Demographics  













Caucasians, n (%) 
Blacks, n (%) 
Asians, n (%) 













Clinical characteristics  
Heart failure, n (%) 3 (10%) 0 (0%) 0.11 
IHD, n (%) 0 (0%) 10 (32.3%) <0.001
Diabetes Mellitus, n (%) 7 (23.3%) 7 (22.6%) 0.81 
Previous stroke/TIA, n (%) 5 (16.7%) 2 (6.5%) 0.26 
Asthma/COPD, n (%) 9 (30%) 4 (12.9%) 0.10
Chronic liver disease, n (%) 0 (0%) 0 (0%) - 
Chronic kidney disease, n (%) 0 (0%) 1 (3.2%) 1.00 
Anaemia, n (%) 1 (3.3%) 1 (3.2%) 1.00 
Thyroid disorder, n (%) 1 (3.3%) 4 (12.9%) 0.35
Hypercholesterolaemia, n (%) 14 (46.7%) 15 (48.4%) 0.89 
Arthritis, n (%) 14 (46.7%) 16 (51.6%) 0.70 
CHA2DS2-VASc score 3 [2 – 4] 3 [2 – 4] 0.56
HAS-BLED score 1 [1 – 1] 1 [1 – 1] 0.18 
Smoking status 
Never smoked, n (%) 
Ex-smoker, n (%) 












None, n (%) 







Height (cm) 169.3 ± 8.4 167.3 ± 10.1 0.40
Weight (kg) 89.6 ± 19.1 87.2 ± 21.7 0.66 
BMI (kg/m2) 31.1 ± 5.1 31.0 ± 6.3 0.95 
Heart rate (bpm) 77 [68 – 86] 62 [58 – 70] 0.003
Systolic BP (mm/Hg) 140 [128 – 148] 144 [134 – 153] 0.24 
Diastolic BP (mm/Hg) 81 ± 13 76 ± 15 0.16 
Mean Arterial Pressure (MAP) (mm/Hg) 101 ± 12 101 ± 16 0.87 
HbA1c (mmol/mol) 41 [38 – 46] 41 [40 – 51] 0.94
CrCl (mL/min) 86.2 ± 30.8  75.9 ± 38.1 0.72 
Ejection fraction (%) 55 [55 – 62] 62 [55 – 68] 0.22
 
Table 4 – Differences in flow mediated dilatation (FMD) between permanent AF and paroxysmal AF groups – cross sectional comparison 
 Permanent AF + hypertension group 
(n = 30) 
Paroxysmal AF + hypertension group
(n = 31) 
P
Baseline diameter (mm) 4.5 [4.2 – 5.0]b 4.8 [4.6 – 5.1]b 0.67
Peak diameter (mm) 4.7 [4.4 – 5.2]b 5.2 [4.6 – 5.3]b 0.49 
Absolute FMD change (mm) 0.1 [0.1 – 0.2]b 0.3 [0.2 – 0.4]b 0.01 
FMD (%) 3.1 [2.3 – 4.8]b 5.9 [4.0 – 8.1]b 0.02 
FMDc (%) 3.9 [2.8 – 5.0]a 5.9 [4.8 – 7.0]a 0.01 
Time to peak diameter (sec) 50 [29 – 85]b 80 [36 – 93]b 0.23 
Shear rate (Positive shear rate area to peak) [sec.-1] 4592 [2278 – 5734]b 4800 [2800 – 8102]b 0.40 
 
Table 5 – Haemodynamic and FMD data for longitudinal comparison of Permanent AF (and hypertension) 
group 
 Permanent AF + 
hypertension group 
(Baseline) 
[n = 30] 
Permanent AF + 
hypertension group 
(Follow up) 
[n = 30] 
p 
Clinical characteristics  Mean ± SD / Median 
[IQR] 
Mean ± SD / Median 
[IQR] 
Weight (kg) 89.6 ± 19.1 90.1 ± 19.4 0.13 
BMI (kg/m2) 31.1 ± 5.1  31.2 ± 5.2 0.11
Heart rate (bpm) 77 ± 18 72 ± 17 0.01 
Systolic BP (mm/Hg) 140 [128 – 148] 131 [122 – 146] 0.03 
Diastolic BP (mm/Hg) 81 ± 13 77 ± 12 0.02 
Mean Arterial Pressure (MAP) (mm/Hg) 100 ± 9 97 ± 13 0.01 
CHA2DS2-VASc score 3 [2 – 4] 3 [2 – 4] 1.00 
HAS-BLED score 1 [1 – 1] 1 [1 – 1] 1.00 
FMD measurements Mean [95% CI]a / 
Median [95% CI]b 
Mean [95% CI]a / 
Median [95% CI]b 
 
Baseline diameter (mm) 4.5 [4.2 – 5.0]b 4.4 [4.1 – 5.1]b 0.34 
Peak diameter (mm) 4.9 [4.5 – 5.3]a 4.8 [4.5 – 5.2]a 0.69
Absolute FMD change (mm) 0.14 [0.11 – 0.25]b 0.20 [0.17 – 0.28]b 0.15 
FMD (%) 3.1 [2.3 – 4.8]b 5.2 [3.9 – 6.5]b 0.09 
FMDc (%) 4.0 [3.0 – 4.9]a 5.1 [4.2 – 6.1]a 0.09
Time to peak diameter (sec) 50 [29 – 85]b 72 [36 – 102]b 0.29 
Shear rate stimulus (Positive shear rate area to 
peak) [sec.-1] 
4592 [2278 – 5734]b  3961 [3526 – 8190]b 0.54 
 
